Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04298138 · ClinicalTrials.gov registry record · Phase 1

Dengue 3 Human Infection Model (DENV-3)

A Phase 1 study, sponsored by State University of New York - Upstate Medical University.

Completed
Registry status
Phase 1
Development phase
9
Enrollment target

NCT04298138 is a Phase 1 study that has completed, run by State University of New York - Upstate Medical University. The registered enrollment target is 9 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04298138, a Phase 1 study, has completed, sponsored by State University of New York - Upstate Medical University.

COMPLETED
Registry status
Phase 1
Development phase
9 participants
Enrollment target

Study Summary

To evaluate the effectiveness of candidate dengue vaccine formulations, it is prudent to develop an appropriate challenge model. This study will examine the safety and effectiveness of the Dengue 3 Live Virus Human Challenge (DENV-3-LVHC) product and assess the ability of this virus strain to elicit an uncomplicated dengue-like illness.

Interventions

  • BIOLOGICAL Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2020-08-03
Est. Completion 2021-12-14
Phase Phase 1

What the Registry Record Tells You About NCT04298138

The ClinicalTrials.gov registry entry for NCT04298138 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York - Upstate Medical University, which has 113 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC) is the first listed.

NCT04298138 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04298138 about?

NCT04298138 is a clinical study titled "Dengue 3 Human Infection Model (DENV-3)". To evaluate the effectiveness of candidate dengue vaccine formulations, it is prudent to develop an appropriate challenge model. This study will examine the safety and effectiveness of the Dengue 3 Live Virus Human Challenge (DENV-3-LVHC) product and assess the ability of this virus strain to elicit...

What is the current status of trial NCT04298138?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2020-08-03. Estimated completion is 2021-12-14.

What interventions are being tested in trial NCT04298138?

The interventions under investigation include: Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC) (BIOLOGICAL).

Who is sponsoring clinical trial NCT04298138?

This trial is sponsored by State University of New York - Upstate Medical University, which has 113 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.